PLIANT THERAPEUTICS INC

PLRX is the Nasdaq ticker for Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company. The stock represents ownership in a business focused on discovering and developing therapies for fibrotic diseases. Because PLRX is a clinical-stage company, its value is closely tied to the progress of its drug pipeline and regulatory milestones rather than commercial product sales. For the latest PLRX details and price, see the quote displayed on this page.

PLRX operates in the biotechnology industry, specifically within the biopharmaceutical sector. The company is engaged in research and development of small molecule therapeutics targeting fibrosis. As a clinical-stage biotech, its activities center on preclinical studies, clinical trials, and regulatory interactions rather than large-scale commercial manufacturing. Industry conditions such as scientific breakthroughs, FDA policies, and peer competition can influence how investors view PLRX.

The current PLRX stock price changes continuously during market hours. To see the latest price, along with the day's change and other real-time data, please refer to the live quote on this page. The quote will reflect the most recent trade and any after-hours movement, if applicable.

PLRX, like many clinical-stage biotech stocks, can be volatile. Its price may react sharply to clinical trial data, regulatory news, financing activities, or changes in the broader biotech sector. Daily price swings can be wider than those of more established, revenue-generating companies. Evaluating historical price ranges and trading volume can help investors understand the stock's typical volatility profile. The 52-week range on this page provides a useful reference.

Valuing PLRX is different from valuing a company with steady earnings, since PLRX is a clinical-stage biotech without product revenue. Traditional metrics like the P/E ratio may not apply. Investors often look at cash reserves, pipeline progress, addressable market size, and comparisons to similar biotech companies. The market capitalization and enterprise value on this page, along with any available financial data, can help frame the valuation.

PLRX faces risks common to clinical-stage biotech companies. These include the possibility that drug candidates fail in clinical trials, regulatory delays or rejections, competition from other therapies, and the need for additional capital to fund research. Because PLRX has no approved products, it may lack commercial revenue, making it dependent on financing. Broader market and economic factors can also affect the stock. Reviewing SEC filings and pipeline updates can help investors assess these risks.